Vivet Therapeutics Presents Interim Data from its Phase 1/2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024

Posted on by

VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology Encouraging safety and tolerability with no serious adverse events reported PARIS, June 5, 2024 /PRNewswire/ — Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.